Achieve Life Sciences Inc (ACHV)

Achieve Life Sciences Inc is trading at $6.83, down 5.01% on the session. The 50 day average sits at $7.45 and the 200 day at $5.64, which puts the stock in a uptrend. RSI is at 46.4, which reads as neutral, and MACD is bullish crossover. Volume is average.

The nearest support is around $6.33 with resistance near $7.48, so that band frames the current range. Average daily movement is roughly $0.40, or about 5.9% of the share price, which is what any stop placement has to allow for. The overall health score of 56 out of 100 combines a trend score of 61, momentum of 59 and a risk score of 42.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.